The therapeutic effect of C1-inhibitor on gut-derived bacterial translocation after thermal injury.
To test the effects of C1-esterase inhibitor in scald burns on bacterial translocation and intestinal damage, standardized deep partial-thickness burns were inflicted on domestic pigs, scalding 30% of the skin surface for 25 s with 75 degrees C hot water. The animals (n = 17; weight 25-35 kg) were divided into three groups: I) the control group (n = 5) without scald burn; II) the group (n = 6) with scald burn; and III) the group with C1-inhibitor (n = 6): scald burn and treatment with C1-inhibitor (C1-INH; BERINERT, Behring, Marburg, Germany). Parameters measured and compared in this model were activity of complement system, hemodynamics, body weight, pathological organ alterations including intestinal lesions, bacterial translocation, and skin damage. C1-INH administration significantly decreased the plasma levels of the specific soluble membrane attack complex (SC5b-9), bacterial translocation, and the degree of intestinal ischemia in the postburn period compared with untreated animals. Moreover, animals treated with C1-INH exhibited a minor degree of organ alterations including damage of the skin and development of edema. The favorable effects of C1-INH may be explained by the protection of the intestinal and dermal microcirculation in the acute phase of thermal injury.
Khorram-Sefat
R
R
The Clinic of Burns and Plastic Surgery, The Technical University of Aachen, Germany.
Goldmann
C
C
Radke
A
A
Lennartz
A
A
Mottaghy
K
K
Afify
M
M
Küpper
W
W
Klosterhalfen
B
B
D000818:Animals; D018988:Bacterial Translocation / Q000187:drug effects*; D001835:Body Weight / Q000187:drug effects; D002056:Burns / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology*; D003174:Complement C1 Inactivator Proteins / Q000494:pharmacology*; D015938:Complement Membrane Attack Complex; D003165:Complement System Proteins / Q000032:analysis; D004064:Digestive System / Q000382:microbiology / Q000473:pathology; D004487:Edema / Q000188:drug therapy; D005243:Feces / Q000382:microbiology; D006023:Glycoproteins / Q000032:analysis; D006439:Hemodynamics / Q000187:drug effects; D007668:Kidney / Q000473:pathology; D008099:Liver / Q000473:pathology; D008168:Lung / Q000503:physiopathology; D008198:Lymph Nodes / Q000382:microbiology; D008297:Male; D012867:Skin / Q000293:injuries* / Q000473:pathology; D013552:Swine; D013778:Tetrazolium Salts; D013844:Thiazoles
D003174:Complement C1 Inactivator Proteins; D015938:Complement Membrane Attack Complex; D006023:Glycoproteins; C047610:SC5b-9 protein complex; D013778:Tetrazolium Salts; D013844:Thiazoles; D003165:Complement System Proteins; C022616:thiazolyl blue